LakeShore Biopharma Announces Extraordinary General Meeting
Ticker: LSBWF · Form: 6-K · Filed: Jul 5, 2024 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Lakeshore Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | Jul 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, corporate-action, foreign-issuer
TL;DR
LakeShore Biopharma calling an EGM, likely for key shareholder votes.
AI Summary
LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a 6-K report on July 5, 2024. The filing includes a press release announcing an upcoming Extraordinary General Meeting. The company is located in Beijing, PRC, and its fiscal year ends on March 31.
Why It Matters
This filing signals upcoming corporate actions or decisions that could impact the company's strategic direction and shareholder value.
Risk Assessment
Risk Level: low — This is a routine filing announcing a meeting, not detailing significant financial changes or operational risks.
Key Numbers
- 001-41598 — Commission File Number (Identifies the specific SEC filing)
Key Players & Entities
- LakeShore Biopharma Co., Ltd. (company) — Registrant
- YS Biopharma Co., Ltd. (company) — Former Company Name
- YishengBio Co., Ltd (company) — Former Company Name
- 001-41598 (dollar_amount) — Commission file number
- July 5, 2024 (date) — Filing Date
FAQ
What is the purpose of the Extraordinary General Meeting announced by LakeShore Biopharma?
The filing does not specify the exact purpose of the Extraordinary General Meeting, only that a press release (Exhibit 99.1) is attached regarding it.
When was LakeShore Biopharma Co., Ltd. formerly known as YS Biopharma Co., Ltd. and YishengBio Co., Ltd.?
The company changed its name from YishengBio Co., Ltd on March 10, 2023, and from YS Biopharma Co., Ltd. on September 12, 2022.
What is LakeShore Biopharma's fiscal year end?
LakeShore Biopharma's fiscal year ends on March 31.
Where is LakeShore Biopharma's principal executive office located?
The principal executive offices are located at Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, PRC.
What type of report is this filing?
This is a Form 6-K report, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Filing Stats: 185 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2024-07-05 07:15:02
Filing Documents
- ea0209005-6k_lakeshore.htm (6-K) — 16KB
- ea020900501ex99-1_lakeshore.htm (EX-99.1) — 13KB
- ea020900501ex99-2_lakeshore.htm (EX-99.2) — 9KB
- 0001213900-24-059250.txt ( ) — 39KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission file number: 001-41598 LAKESHORE BIOPHARMA CO., LTD (Exact name of registrant as specified in its charter) Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, PRC Tel: 010-89202086 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F EXHIBITS Exhibit No. Description 99.1 Press Release – LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders’ Requisition 99.2 Notice of Extraordinary General Meeting 1 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LakeShore Biopharma Co., Ltd By: /s/ Hui Shao Name: Hui Shao Title: Director and Co-Chief Executive Officer Date: July 5, 2024 2